RE 02
Alternative Names: RE-02Latest Information Update: 07 Sep 2023
At a glance
- Originator Reconnect Labs
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 31 Jul 2023 Preclinical trials in Unspecified in Switzerland (unspecified route) prior to July 2023
- 31 Jul 2023 Reconnect Labs plans a phase I trial (In volunteers, Treatment-experienced) in August 2023 (NCT05979727)